What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination?
- 19 June 2017
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 10 (5) , a029397
Abstract
A key goal of HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bnAbs) targeted to the vulnerable regions of the HIV envelope. BnAbs develop over time in ∼50% of HIV-1-infected individuals. However, to date, no vaccines have induced bnAbs and few or none of these vaccine-elicited HIV-1 antibodies carry the high frequencies of V(D)J mutations characteristic of bnAbs. Do the high frequencies of mutations characteristic of naturally induced bnAbs represent a fundamental barrier to the induction of bnAbs by vaccines? Recent studies suggest that high frequencies of V(D)J mutations can be achieved by serial vaccination strategies. Rather, it appears that, in the absence of HIV-1 infection, physiologic immune tolerance controls, including a germinal center process termed affinity reversion, may limit vaccine-driven bnAb development by clonal elimination or selecting for mutations incompatible with bnAb activity.Keywords
This publication has 47 references indexed in Scilit:
- Progress in HIV-1 vaccine developmentCurrent Opinion in HIV and AIDS, 2013
- Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesJournal of Experimental Medicine, 2013
- HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal LineagesJournal of Virology, 2012
- B-cell–lineage immunogen design in vaccine development with HIV-1 as a case studyNature Biotechnology, 2012
- Follicular Helper CD4 T Cells (TFH)Annual Review of Immunology, 2011
- Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent ReporterCell, 2010
- Origin of Chromosomal Translocations in Lymphoid CancerCell, 2010
- Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic toleranceProceedings of the National Academy of Sciences, 2009
- Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood DonorsJournal of Virology, 2009
- Autoreactivity in Human IgG+ Memory B CellsImmunity, 2007